Back to Top Skip to main content Skip to sub-navigation

DOD participates in new COVID-19 antibody combination prevention trial

Woman gets blood drawn Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | MHS Toolkits and Branding Guidance

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

COVID-19 Vaccination Card Second Shot

Infographic
5/27/2021
Graphic saying that keeping track of your vaccination card is important. Includes a helpful tips section, a link to www.tricare.mil/covidvaccine, and what to do when you didn’t get your vaccination card or don’t have a copy. The TRICARE logo is on the bottom right of the page.

Keep track of your vaccination card. Tips include keeping your card on you and taking a picture of it as a backup copy.

Recommended Content:

COVID-19 Vaccine Toolkit | Costs and Documentation | Coronavirus

Adolescents ages 12 and older eligible for COVID-19 vaccinations

Article
5/27/2021
Son of military personnel receiving his COVID-19 vaccine

Pfizer vaccine now authorized for children 12 and older.

Recommended Content:

Children's Health | COVID-19 Vaccine Toolkit | Coronavirus

Town Hall May 26 2021

Video
5/26/2021
Town Hall May 26 2021

RADM Anne Swap will discuss the National Capital Region's response to COVID-19

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | National Capital Region Market

Got Your 6 - May 26, 2021

Video
5/26/2021
Video screen image for the May 26, 2021 Got Your Six video

"Got Your 6" is TRICARE's COVID-19 vaccine video series that delivers important information and updates, three times a month. It includes the latest information about DoD vaccine distribution, the TRICARE health benefit, and vaccine availability for a DoD-affiliated, and TRICARE beneficiary audience.

Recommended Content:

MHS Toolkits and Branding Guidance | MHS Toolkits and Branding Guidance | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

COVID-19 Town Hall with RADM Anne M. Swap

Article
5/24/2021
MHS and Military OneSource NCR COVID-19 Town Hall with Rear Admiral Anne M. Swap, Director, National Capital Medical Directorate, Wednesday, May 26 at 11:50 a.m. ET

The purpose of this event is to inform National Capital Region (NCR) beneficiaries of DHA’s efforts with battling coronavirus (COVID-19) and encourage them to not delay care.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts | MHS and Military OneSource To Your Health

Adirim, Place laud DHA response to COVID-19 in briefing

Article
5/21/2021
Defense Health Agency Director Lt. Gen. (Dr.) Ronald J. Place speaking at a press conference

Dr. Terry Adirim, acting assistant secretary of defense for health affairs, and Army Lt. Gen. (Dr.) Ronald J. Place, director of the Defense Health Agency, provided a COVID-19 update during a Pentagon press briefing.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

Sailors continue to receive COVID-19 vaccine

Article
5/20/2021
Military personnel wearing a face mask receiving the COVID-19 vaccine

Sailors continue to voluntarily receive one of the three available COVID-19 vaccines.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus | COVID-19 Vaccine Efforts

Vax Facts: I'm fully vaccinated. What can I do?

Video
5/20/2021
DHA Seal

If you're fully vaccinated, there are options for safer activities. Watch to learn what activities you can resume once you're fully vaccinated.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts

Vax Facts: Risk and Precautions

Video
5/20/2021
DHA Seal

If you're fully vaccinated, there are options for safer activities. Watch to learn what activities you can resume once you're fully vaccinated.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts

Vax Facts: Recommendations for Pregnancy

Video
5/20/2021
DHA Seal

The COVID vaccine is recommended for pregnant people. Watch to learn how your doctor can help you make the best decision for you and your baby.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts

Vax Facts: How Long Does Protection Last

Video
5/20/2021
DHA Seal

We're not sure how long you're protected against COVID, although researchers are continuing to study the vaccine. Watch to learn how to get updates on how long your protection lasts.

Recommended Content:

COVID-19 Vaccine Toolkit | COVID-19 Vaccine Efforts

MHS quickly adapted to improve patient experience during pandemic

Article
5/19/2021
Military health personnel waiting for the next phone call on the COVID-19 advice line

MHS adapted technology to boost patient experience during pandemic

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

DHA Director visits MCAGCC to hear from the ‘Boots on the Ground’

Article
5/19/2021
Military personnel wearing face masks walking

DHA Director visits Marine Corps Air Ground Combat Center Twentynine Palms.

Recommended Content:

MHS GENESIS | Military Health System Transformation | Coronavirus | COVID-19 Vaccine Toolkit

Palliative care provides comfort to COVID-19 patients, families

Article
5/17/2021
Military health personnel taking care of a patient

Medical Center team develops palliative care toolkit for COVID-19 patients

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus

Military medicine heroes recognized for COVID-19 pandemic response

Article
5/17/2021
Photo of the virtual "Heroes of Military Medicine" award ceremony

COVID-19 pandemic will affect military medicine for years to come, DHA Director Place tells HJF awards ceremony.

Recommended Content:

COVID-19 Vaccine Toolkit | Coronavirus
<< < 1 2 3 4 5  ... > >> 
Showing results 61 - 75 Page 5 of 40

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.